Christian Scherrer
Investment Manager @ Kinnevik
London, United Kingdom
Christian Scherrer is a Series C investor at Kinnevik in London focused on Health Care and Therapeutics. Christian Scherrer serves as an Investment Manager at Kinnevik.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 64%
Last updated:
For AI agents: llms.txt
Industries Christian Scherrer invests in
Stages Christian Scherrer invests in
Countries Christian Scherrer invests in
Investment Focus
Industry
- Health Care 3 (27%)
- Therapeutics 2 (18%)
- Biotechnology 2 (18%)
- Personal Health 2 (18%)
- Medical 1 (9%)
Stage
- Series C 3 (27%)
- Series D 3 (27%)
- Series B 2 (18%)
- Series E 1 (9%)
- Secondary Market 1 (9%)
Country
- United States 4 (36%)
- United Kingdom 1 (9%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Oviva
|
Oviva is digitizing the treatment of type 2 diabetes and obesity through a unique behavior change platform.They have developed unique, personalised behaviour change programmes that combine smartphone app and learning portals to support dietitian-led behaviour change for conditions such as type 2 diabetes and complex obesity. Their approach allowspatients to achieve a better health outcome without having to attend clinic appointments, whilst saving health systems significant sums by preventing the development of complications related to these health conditions.Oviva was founded in 2013 and is based in Altendorf (Switzerland) with offices in Zurich (Switzerland), London (United Kingdom), and Berlin (Germany). | $233.7M / Series D / Jan 22, 2026 | |
|
Oviva
|
Oviva is digitizing the treatment of type 2 diabetes and obesity through a unique behavior change platform.They have developed unique, personalised behaviour change programmes that combine smartphone app and learning portals to support dietitian-led behaviour change for conditions such as type 2 diabetes and complex obesity. Their approach allowspatients to achieve a better health outcome without having to attend clinic appointments, whilst saving health systems significant sums by preventing the development of complications related to these health conditions.Oviva was founded in 2013 and is based in Altendorf (Switzerland) with offices in Zurich (Switzerland), London (United Kingdom), and Berlin (Germany). | Secondary Market / Jan 22, 2026 | |
Enveda Biosciences
|
Enveda Biosciences is a biotechnology company building new medicines from plants. It harnesses the complexity of the natural world to tackle today’s biggest healthcare challenges. With the help of the advancements in knowledge graphs, machine learning, and metabolomics, they discover the next generation of small molecules. Its technologiessystematize the discovery of small molecules and novel targets for complex diseases. By probing novel chemical space and mechanisms of action, they are breaking the status quo for challenging diseases with a need for effective treatments, such as fibrosis or neurodegeneration.Enveda, launched in 2019, is based in San Francisco, California. | $150M / Series D / Sep 04, 2025 | |
Strand Therapeutics
|
Strand Therapeutics is a developer of a biotechnology platform intended to create gene therapies powered by synthetic biology.The company's offerings include immunotherapies to help cells produce target cancer-killing proteins during immunotherapy, enabling patients to improve their body's immune system to fight cancer. | $153M / Series B / Aug 03, 2025 | |
|
Enveda Biosciences
|
Enveda Biosciences is a biotechnology company building new medicines from plants. It harnesses the complexity of the natural world to tackle today’s biggest healthcare challenges. With the help of the advancements in knowledge graphs, machine learning, and metabolomics, they discover the next generation of small molecules. Its technologiessystematize the discovery of small molecules and novel targets for complex diseases. By probing novel chemical space and mechanisms of action, they are breaking the status quo for challenging diseases with a need for effective treatments, such as fibrosis or neurodegeneration.Enveda, launched in 2019, is based in San Francisco, California. | $130M / Series C / Nov 21, 2024 | |
Spring Health
|
Spring Health is a global mental health company built on one AI-native platform so care follows individuals across every job, move, health plan, and life stage. Independently validated by JAMA Network Open and the Validation Institute, with 92% of members reliably improved or recovered from depression or anxiety and employers seeing a 52%reduction in total mental health claims costs, Spring Health provides personalized lifelong mental health support across self-guided tools, coaching, therapy, medication management, and specialty care. More than 170 million people worldwide have access to Spring Health, which is trusted by leading employers, health plans, and channel partners, including Highmark, Target, The Coca-Cola Company, BlackRock, Microsoft, Pfizer, and Wawa. | $100M / Series E / Jul 31, 2024 | |
|
Enveda Biosciences
|
Enveda Biosciences is a biotechnology company building new medicines from plants. It harnesses the complexity of the natural world to tackle today’s biggest healthcare challenges. With the help of the advancements in knowledge graphs, machine learning, and metabolomics, they discover the next generation of small molecules. Its technologiessystematize the discovery of small molecules and novel targets for complex diseases. By probing novel chemical space and mechanisms of action, they are breaking the status quo for challenging diseases with a need for effective treatments, such as fibrosis or neurodegeneration.Enveda, launched in 2019, is based in San Francisco, California. | $55M / Series B / Jun 14, 2024 | |
Transcarent
|
Transcarent is a consumer-directed health and care platform for employees of self-insured employers and their families. Using a combination of software, technology, health guides, and data science, the company helps consumers with unbiased information, trusted guidance, and access to high-value care. | $126M / Series D / May 02, 2024 | |
|
Enveda Biosciences
|
Enveda Biosciences is a biotechnology company building new medicines from plants. It harnesses the complexity of the natural world to tackle today’s biggest healthcare challenges. With the help of the advancements in knowledge graphs, machine learning, and metabolomics, they discover the next generation of small molecules. Its technologiessystematize the discovery of small molecules and novel targets for complex diseases. By probing novel chemical space and mechanisms of action, they are breaking the status quo for challenging diseases with a need for effective treatments, such as fibrosis or neurodegeneration.Enveda, launched in 2019, is based in San Francisco, California. | $51M / Series B / Apr 20, 2023 | |
|
Transcarent
|
Transcarent is a consumer-directed health and care platform for employees of self-insured employers and their families. Using a combination of software, technology, health guides, and data science, the company helps consumers with unbiased information, trusted guidance, and access to high-value care. | $200M / Series C / Jan 11, 2022 | |
| See all 11 investments → | |||
Co-Investors
About Kinnevik
Kinnevik is an industry-focused investment company with an entrepreneurial spirit. Its purpose is to build digital consumer businesses that provide more and better choices. The company does this by working in partnership with talented founders and management teams to create, invest in, and lead fast-growing businesses in developed and emergingmarkets.Kinnevik believes in delivering both shareholder and social value by building well-governed companies that contribute positively to society. Kinnevik was founded in 1936 by the Stenbeck, Klingspor, and von Horn families. Kinnevik's shares are listed on Nasdaq Stockholm's list for large-cap companies under the ticker codes KINV A and KINV B.
Kinnevik Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Andreas Bernstrom
Senior Investment Director
|
|||
Magnus Jakobson
Corporate Finance Director
|
|||
Ola Nordbye
Venture & Growth Investor
|
|||
Anders Strandberg
Legal Professional
|
|||
|
Christian Scherrer
Investment Manager
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Christian Scherrer invest in?
Christian Scherrer invests primarily in Health Care, Therapeutics and Biotechnology startups, most often at Series C and Series D stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Christian Scherrer last invest?
The most recent investment recorded for Christian Scherrer closed in Jan 2026. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
